New basal insulins in T2DM: cost not increased, hypoglycaemia reduced
- PDF / 188,460 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 63 Downloads / 176 Views
PharmacoEconomics & Outcomes News 867, p27 - 28 Nov 2020 New basal insulins in T2DM: cost not increased, hypoglycaemia reduced Use of newly introduced basal insulins does not appear to increase direct treatment costs in patients with type 2 diabetes mellitus (T2DM) and may reduce the incidence of hypoglycaemia, according to findings of a Sanofi Francefunded study published in PharmacoEconomics - Open. The observational study performed by community pharmacists in 600 randomly selected Pharmaccess pharmacies in France between November 2017 and February 2018 investigated direct costs of insulin therapy in 1933 adults with T2DM receiving recently marketed basal insulins (insulin glargine 300 U/ml [Gla-300; Toujeo], biosimilar insulin glargine 100 U/ml [Gla-100 biosimilar; Abasaglar] and insulin degludec/liraglutide [IDegLira; Xultophy]), or established basal or intermediate insulins (branded insulin glargine 100 U/ml [branded Gla-100; Lantus], insulin detemir [Levemir] and insulin suspension isophane [NPH]). Direct costs included medication costs, diabetes nurse costs, and costs for self-monitoring blood glucose. Gla-300 accounted for 62% of prescriptions for novel basal insulins, while branded Gla-100 accounted for 69% of prescriptions for established insulins. The incidence of hypoglycaemia requiring assistance was lower with novel insulins than with established insulins (11.2% vs 22.2%; p
Data Loading...
